Experimental and clinical psychopharmacology
-
Exp Clin Psychopharmacol · Apr 2019
Initial application of a human laboratory model for estimating the motivational substitutability of e-cigarettes for combustible cigarettes.
This pilot study tested a novel human laboratory model for estimating the extent to which electronic cigarettes (e-cigarettes) serve as motivational substitutes for combustible cigarettes. The model assesses 3 parameters of substitutability, including the: (a) increase in motivational reward value of e-cigarettes after tobacco deprivation; (b) reduction in the reward value of combustible cigarettes after e-cigarette administration; and (c) comparability of the withdrawal-suppressing effects of e-cigarettes versus combustible cigarettes. Dual users (daily smokers, vaped 4+ days/week, M age = 35.3) attended 4 visits after 16-h tobacco product abstinence. ⋯ Relative to deprivation, vaping suppressed withdrawal-related negative affect, smoking and vape urge, and anhedonia (ds ≥ .54). The magnitude of vaping-induced and smoking-induced withdrawal suppression did not significantly differ for all outcomes other than smoking urge, which was more strongly reduced by smoking (d = -1.57) than vaping (d = -.64). Future application and extension of this model may advance tobacco regulatory science and policy addressing e-cigarette use among smokers. (PsycINFO Database Record (c) 2019 APA, all rights reserved).
-
Exp Clin Psychopharmacol · Aug 2018
Randomized Controlled TrialInterim buprenorphine treatment during delays to comprehensive treatment: Changes in psychiatric symptoms.
Prevalence of depression, anxiety, and mood disorders among individuals with opioid use disorder far exceeds that of the general population. While psychiatric symptoms often improve upon entry into opioid treatment, this has typically been seen with treatments involving psychosocial counseling. In this secondary analysis, we examined changes in psychiatric symptoms during a randomized clinical trial evaluating an interim buprenorphine treatment without counseling among individuals awaiting entry into comprehensive treatment. ⋯ On all measures, IBT participants reported significantly reduced psychiatric severity at the 4-, 8-, and 12-week assessments relative to baseline. In contrast, there were no significant changes in psychiatric symptoms among WLC participants. IBT without counseling may improve psychiatric distress among waitlisted individuals with opioid use disorder. (PsycINFO Database Record
-
Exp Clin Psychopharmacol · Apr 2018
Naltrexone maintenance fails to alter amphetamine effects on intracranial self-stimulation in rats.
Pharmacotherapy to treat stimulant use disorders continues to be an unmet medical need. Some evidence supports both the role of opioids in mediating abuse-related amphetamine effects and the potential utility of opioid antagonists as therapeutic candidates for treating amphetamine abuse. This study used intracranial self-stimulation (ICSS) to evaluate effects of exposure to and termination of naltrexone maintenance on rewarding amphetamine effects in an ICSS procedure in rats. ⋯ Additionally, dose-effect curves for morphine and amphetamine were determined again 24 hr after pump removal. Our results suggest that (a) exposure to and termination of naltrexone maintenance do not affect baseline ICSS responding, (b) naltrexone doses sufficient to antagonize morphine did not alter amphetamine or cocaine effects, and (c) termination of naltrexone treatment produced weak evidence for increased morphine sensitivity but no change in amphetamine effects. Our results do not support naltrexone as a pharmacotherapy for amphetamine and cocaine abuse and also suggest that termination from chronic naltrexone does not increase sensitivity to abuse-related morphine or amphetamine effects in ICSS. (PsycINFO Database Record
-
Exp Clin Psychopharmacol · Apr 2018
An assessment of concurrent cannabidiol and Δ⁹-tetrahydrocannabinol administration in place aversion and taste avoidance conditioning.
Rising interest in medical marijuana has prompted research into its phytocannabinoid constituents, particularly Δ⁹-tetrahydrocannabinol (THC) and cannabidiol (CBD). Coadministration of CBD with THC has been shown to modulate a number of THC's effects, including its negative stimulus properties (e.g., anxiety, paranoia, psychosis) in a clinical setting. The present series of experiments extended these analyses by examining the ability of CBD to impact the aversive effects of THC as assessed in a combined taste and place conditioning procedure. ⋯ Similar to the initial assessment, CBD had no effect on THC-induced place or taste conditioning at either dose ratio. These results may reflect the specific phytocannabinoid dose ratios examined or species differences in cannabinoid action. The current findings further suggest that altering CBD content in medicinal cannabis will likely have minimal effects in terms of tolerability. (PsycINFO Database Record
-
Exp Clin Psychopharmacol · Oct 2017
Randomized Controlled TrialElectronic cigarette user plasma nicotine concentration, puff topography, heart rate, and subjective effects: Influence of liquid nicotine concentration and user experience.
Electronic cigarette (ECIG) nicotine delivery and other effects may depend on liquid nicotine concentration and user experience. This study is the first to systematically examine the influence of ECIG liquid nicotine concentration and user experience on nicotine delivery, heart rate, puff topography, and subjective effects. Thirty-three ECIG-experienced individuals and 31 ECIG-naïve cigarette smokers completed 4 laboratory conditions consisting of 2, 10-puff bouts (30-sec interpuff interval) with a 3.3-V ECIG battery attached to a 1.5-Ω "cartomizer" (7.3 W) filled with 1 ml ECIG liquid. ⋯ Between-group differences were likely due to longer puffs taken by experienced ECIG users: collapsed across condition, mean puff duration was 5.6 sec (SD = 3.0) for ECIG-experienced and 2.9 (SD = 1.5) for ECIG-naïve individuals. ECIG use also suppressed nicotine/tobacco abstinence symptoms in both groups; the magnitude of abstinence symptom suppression depended on liquid nicotine concentration and user experience. These and other recent results suggest that policies intended to limit ECIG nicotine delivery will need to account for factors in addition to liquid nicotine concentration (e.g., device power and user behavior). (PsycINFO Database Record